OCUL Ocular Therapeutix Inc

Price (delayed)

$6.08

Market cap

$941.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.11

Enterprise value

$531.48M

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation ...

Highlights
The revenue has grown by 16% YoY and by 2.4% from the previous quarter
Ocular Therapeutix's gross profit has increased by 15% YoY and by 2.4% QoQ
The debt has grown by 15% YoY but it has contracted by 11% from the previous quarter
The company's EPS fell by 10% QoQ but it rose by 2.6% YoY
The net income has declined by 43% since the previous quarter and by 30% year-on-year

Key stats

What are the main financial stats of OCUL
Market
Shares outstanding
154.89M
Market cap
$941.72M
Enterprise value
$531.48M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.21
Price to sales (P/S)
13.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.88
Earnings
Revenue
$59.84M
EBIT
-$101.65M
EBITDA
-$98.23M
Free cash flow
-$87.11M
Per share
EPS
-$1.11
Free cash flow per share
-$0.66
Book value per share
$2.75
Revenue per share
$0.45
TBVPS
$4.08
Balance sheet
Total assets
$538.95M
Total liabilities
$130.96M
Debt
$74.41M
Equity
$407.98M
Working capital
$495.53M
Liquidity
Debt to equity
0.18
Current ratio
21.39
Quick ratio
21.04
Net debt/EBITDA
4.18
Margins
EBITDA margin
-164.1%
Gross margin
91%
Net margin
-192.6%
Operating margin
-152.8%
Efficiency
Return on assets
-42.9%
Return on equity
-90.4%
Return on invested capital
-103.7%
Return on capital employed
-19.8%
Return on sales
-169.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OCUL stock price

How has the Ocular Therapeutix stock price performed over time
Intraday
10.75%
1 week
20.63%
1 month
-3.34%
1 year
30.47%
YTD
36.32%
QTD
-33.19%

Financial performance

How have Ocular Therapeutix's revenue and profit performed over time
Revenue
$59.84M
Gross profit
$54.45M
Operating income
-$91.45M
Net income
-$115.27M
Gross margin
91%
Net margin
-192.6%
The net income has declined by 43% since the previous quarter and by 30% year-on-year
The net margin has contracted by 39% from the previous quarter and by 12% YoY
The revenue has grown by 16% YoY and by 2.4% from the previous quarter
Ocular Therapeutix's gross profit has increased by 15% YoY and by 2.4% QoQ

Growth

What is Ocular Therapeutix's growth rate over time

Valuation

What is Ocular Therapeutix stock price valuation
P/E
N/A
P/B
2.21
P/S
13.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.88
The company's EPS fell by 10% QoQ but it rose by 2.6% YoY
OCUL's price to book (P/B) is 95% less than its last 4 quarters average of 42.1 and 91% less than its 5-year quarterly average of 24.4
The stock's P/S is 55% below its 5-year quarterly average of 29.9 but 41% above its last 4 quarters average of 9.5
The revenue has grown by 16% YoY and by 2.4% from the previous quarter

Efficiency

How efficient is Ocular Therapeutix business performance
Ocular Therapeutix's return on equity has surged by 69% QoQ and by 60% YoY
The company's return on sales fell by 43% QoQ and by 7% YoY
OCUL's return on invested capital is down by 38% since the previous quarter but it is up by 6% year-on-year
The return on assets has grown by 26% year-on-year and by 12% since the previous quarter

Dividends

What is OCUL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OCUL.

Financial health

How did Ocular Therapeutix financials performed over time
Ocular Therapeutix's total assets has surged by 114% QoQ
Ocular Therapeutix's total liabilities has decreased by 19% from the previous quarter but it has increased by 10% YoY
The debt is 82% less than the equity
The company's debt to equity has shrunk by 97% YoY and by 80% QoQ
The debt has grown by 15% YoY but it has contracted by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.